Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CFDA Plans Reforms to Speed up Drug Reviews

publication date: Jul 25, 2014
The Center for Drug Evaluation at the CFDA will begin outsourcing reviews for generic drug approvals to speed up the process, said Yin Li, Deputy Director of the CFDA at a recent conference. The outsourcing will be either to China’s provincial drug agencies or independent third parties. The agency will also consider raising application fees, partly to discourage the many filings for generic drugs that already have multiple suppliers. In addition, the CDFA is being advised to allow new drugs to begin clinical trials if the agency does not approve the IND filing within 90 days. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital